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Abstract 
This article is taken from an interview with Professor Gustav Victor Rudolf Born 
(known as Gus), and focuses on his personal reflections and his distinguished 
career.  Prof Born’s innovative research led to the development of a pioneering 
device, the aggregometer, which opened up the field of platelet research.  In this 
article, Prof Born gives his modest insight into the early stages of his career and the 
impact Hiroshima had on his decision to work on thrombosis and haemostasis.  He 
details the key events that led to development of a machine which had a 
revolutionary effect on diagnosing platelet-related diseases and the development of 
antiplatelet agents, thereby making it a world-wide success and saving so many 
lives. 
 
Gus Born: the early years 
Gus was born in 1921 into a middle-class family in Göttingen, Germany, to Hedwig 
Born (née Ehrenberg) and Max Born.  Gus’s mother was a writer and poet and his 
father was renowned in the scientific community, as he was one of the founders of 
quantum mechanics (for which he received the Nobel Prize in Physics in 1954). In 
September 1933, when Gus was just twelve years old, due to the unrest in Germany, 
the Born family were forced to leave their home.  Gus’s father, who was a Jew, had 
sought guidance from his close friend, Albert Einstein, who advised Max to leave 
Germany at once.1  Gus’s father had a job offer at the University of Cambridge, 
which he accepted, and the family relocated to England. 
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“The Born family owes everything to Britain – our very lives when the British people 
first took us in, and again later when Churchill’s courage and steadfastness 
prevented a German invasion, as well as everything else – livelihood, friendship and 
love.  No wonder that the Born’s love and cherish their adopted country!” 2  
Gus, had aspirations of becoming a historian of democratic institutions, he was very 
interested in Victorian times and was a self-confessed expert on Gladstone and 
Disraeli, however Gus’s father foresaw the war and advised him to study medicine 
“then you won’t need to kill people and you are less likely to be killed yourself”.  Gus 
thought it was sound advice; he therefore went on to study medicine in Edinburgh.  
Gus qualified in the height of the war in January 1943. The family had been 
naturalised before the war and so after six months residency Gus was called up into 
the army, upon which he served nearly four years in the Far East as a Medical 
Officer in the Royal Army Medical Corps.  When the war ended, Gus was on the 
occupation force for Japan and was one of the first three medical doctors to attend 
Hiroshima after the atom bomb had been dropped; this was obviously a horrendous 
and very emotional time, Gus stated “it’s something that you never forget”.  Gus saw 
first-hand the people who had been killed immediately by the bomb, but there were 
also thousands dying of bleeding, their bone marrow decimated by the radiation and 
their platelets not clotting.  Horrifically there was nothing that could be done about it.  
That was the driving force for Gus’s interest in platelets, to find a way to save future 
lives. 
Family and inspirations 
Throughout Gus’s career, it was apparent that fellow prominent scientists influenced 
his work a great deal. However, family was hugely important to him; he spoke fondly 
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about his wife, Faith (née Maurice-Williams), a doctor, and Gus reminisced about his 
brilliant father, who was a warm and friendly person described as “humble and 
brave”.  His father had the choice of becoming a professional pianist but was given a 
maths PhD problem to solve, and solving this took him down an academic route 
instead.  Nonetheless, alongside science, music has always been part of the Born 
family life; Gus himself was an accomplished flute player and played semi-
professionally in Oxford, he even took his flute with him to war.  Gus has five 
children, two of whom are prominent in their arts careers; Gus’s daughter, Georgina 
Born, is a Professor of Music and Anthropology at the University of Oxford, and 
Gus’s son, Sebastian Born, was an associate director of London’s National Theatre.   
Pioneering the way for platelet research 
Gus’s curiosity in platelets was piqued when after the war he became a DPhil 
student in the Pharmacology Department at the University of Oxford.  As a 
postdoctoral researcher, Gus worked with a well-known biochemist, Hugh Blaschko, 
on the then recently discovered association of adrenaline with adenosine 
triphosphate (ATP) in adrenal granules.3   It was during this time that Gus had an 
idea; he had heard that platelets had large amounts of amine (5-hydroxytryptamine 
[5-HT], also known as serotonin) and he wondered whether the storage in platelets 
was the same as the adrenal for adrenaline, and it turned out that his hypothesis was 
correct.  Gus’s first publications were on the storage of 5-HT in platelets. 
Gus was interested in experimental pathology and so went on to work at the Sir 
William Dunn School, University of Oxford (he spent many years at Oxford, up until 
he was awarded a Chair position at the Royal College of Surgeons in 1960; for an 
appreciation of Gus’s research path, see Fig 1 in Nurden et al.4)  Initially at the Sir 
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William Dunn School of Pathology, Gus worked with Howard Florey, Professor of 
Pathology (who helped develop penicillin and was awarded a Nobel Prize for this 
work in 1945).   
“Howard Florey to this day is my hero.” 
Gus talked fondly about Florey, recalling that he was very much a no nonsense man, 
with a wonderful sense of humour; Gus was in awe of the fact that Florey was 
responsible for penicillin around the world during the last half-century, when Florey 
took it from Fleming’s discovery to developing the drug.   
Florey mentored Gus and suggested to Gus that he should complete a year in 
London learning biochemistry.  Gus gained the experience and went back to Florey 
who sent him to work with John Barnes at the Toxicology Unit of the Medical 
Research Council (MRC).  At the MRC, Gus recalled one notable episode when Dr 
John Parker, who came from a very poor background and worked his way up, was 
offered a very lucrative position twice his salary at the Military Toxicology Unit in 
Porton Downs Science Park, but he turned it down as “he didn’t want anything to do 
with poisoning people”.  Gus always remembered this and was impressed with 
John’s ethos and stood by it in his life. 
After 2½ years at the Toxicology Unit, Professor Geoffrey Dawes FRS, from the 
Nuffield Institute of Medical Research offered Gus a job with him in Oxford 
(Professor Dawes later went on to become the Director of the Nuffield Institute for 
nearly 40 years).  For the next 3 years, Gus worked at the Nuffield Institute, helping 
out with Professor Dawes “brilliant work” on new-born lambs;5 Gus’s name is on 
many papers from that period of a mutually successful endeavour.  Professor Dawes 
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was very generous with Gus’s time, and allowed him to also carry out platelet 
research; thus in 1953, Gus started working on platelets. 
The development of the aggregometer 
Gus gained his DPhil in 1951 and during this time, in, what Gus describes as his 
“very boring PhD”, he was measuring the effects of an extracellular enzyme 
(exoenzyme) on bacteria.6 He had a suspension of bacteria which was turbid, and as 
he added the enzyme, the suspension cleared. Gus had an idea: “wouldn’t that be 
nice to follow the method with the platelet aggregation, because that’s what platelets 
do as their function”.  Gus then devised a “simple, little device”, and it worked well; 
consequently, this was the first aggregometer. 
In 1960, Gus was given his own department in the Royal College of Surgeon’s in 
London; he took under his wing a “brilliant and lovely” Polish man called 
Zabikowszki, who was Gus’s workshop technician.  Together they built the very first 
aggregometer.  The first paper, which detailed the use of an aggregometer, was in 
Nature in 1962 (Figure 1);7 this has been cited over four thousand times.   
Initial aggregometry traces were recorded as individual points at fixed time intervals, 
which Gus simply relayed by hand without any curve smoothing.  This turned out to 
be ingenious; indeed it allowed Michael Oliver, Professor of Medicine from the 
University of Edinburgh, Gus’s friend and co-worker, to notice an inflexion in the 
curve, a fact that was missed by Gus Born in his early work. This gave rise to the 
notion of the all-important secondary phase of aggregation, now vastly recognised as 
key in platelet response amplification, and the target of clinically-used antiplatelet 
therapy such as aspirin and ADP P2Y12 receptor inhibitors. Gus discussed it good-
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naturedly, as “something he had completely missed”, and was delighted that Michael 
Oliver and his co-workers discovered it, described it, and that many people worked 
on it. 
Gus initially thought the aggregometer was a “toy” just to use for platelet work, and 
then it became a major success. Gus was never tempted to patent the 
aggregometer, and does not regret it; Gus remembers as a student of Florey’s, that 
Florey himself did not patent penicillin. 
“Florey said that you shouldn’t patent anything in medicine”. 
Life after the invention of the aggregometer  
 In many ways, the aggregometer opened up a field of research; prior to the 
aggregometer, researchers did not know how to work with platelets. There was a lot 
of industry interest in the instrument, at least twelve manufacturers followed suit and 
started making the machines. Companies would exhibit the machines at conferences 
all over the world; Gus would often attend these meetings and would visit the 
companies’ stands.  Once, Gus was even given one of the machines for free! 
From the invention of the aggregometer, much of the basic information came from 
Gus’s lab; most importantly, Gus and Michael Cross discovered the first inhibitors, 
they worked very well, particularly adenosine (Figure 2).8 Gus went on to refine the 
aggregometer, for example, with the use of the firefly extract for ATP release from 
platelets; Gus was the first person in Britain to measure ATP with firefly extract. 
Tragically, Michael Cross was killed in a plane crash.  This was a huge loss to 
Gus’ss team,9 but the team had to continue and as a matter of course they looked at 
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anti-thrombotic/anti-platelet drugs.  Gus carried out a lot of work in vivo, and the first 
anti-platelet effects he actually tried out on himself, taking aspirin!10  
For Gus, the aggregometer was a means to an end; he had scientific and medical 
questions to answer which he could do with his machine. He was happy to 
collaborate and contribute to scientific discoveries.  Thus, when Helen Payling 
Wright, who was working on platelets and vitamin C, heard about the machine, Gus 
welcomed the collaboration and happily worked on platelets and scurvy. They 
discovered together that scorbutic platelets don’t aggregate well and they went on to 
publish a paper on platelets and scurvy in The Lancet in 1967.11 
Gus talked fondly of his close friend, Sir John Vane; in 1970 Vane (who, at the time 
was a Reader in Gus’s department), came into Gus’s office and declared, “Gus, I 
know how aspirin works!”. That day, he performed the experiment using the 
superfusion technique, and he showed that aspirin induces a formation of what had 
just been called prostaglandins, by the gut.  By evening the discovery had been 
made, which played a key role in the award of the Nobel prize in 1982 with Sune 
Bergström and Bengt Samuelsson for "their discoveries concerning prostaglandins 
and related biologically active substances”. 
Vane also discovered prostacyclin and its inhibitory effects on platelets, which he 
described with the use of the Born aggregometer.12 The whole discovery of 
prostaglandins and their biological effects Gus described as “wonderful”.  These are 
some of many examples where Gus lent his considerable intellect and expertise, 
with insatiable curiosity, good humour and humility. 
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Concluding remarks 
The journey to the invention of the aggregometer came out of a strong desire to help 
people after seeing the horrors of war. Gus’s flashes of perception and 
accomplishment bely the fact that Gus still referred to his invention as a “hyper-
simple machine”; this machine, which has in fact saved so many people’s lives 
through the discovery of antiplatelet drugs. 
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Figure legends 
Figure 1: The first published platelet aggregation tracing in response to ADP, 
using the Born aggregometer  
Reprinted by permission from Springer Nature; Born GVR. Aggregation of Blood 
Platelets by Adenosine Diphosphate and its Reversal. Copyright Nature (1962) 
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Figure 2: The effect of adenosine on ADP-induced platelet aggregation  
Reprinted by permission from Proceedings of the Physiological Society; Born GVR & 
Cross MJ. Inhibition of the aggregation of blood platelets by substances related to 
adenosine diphosphate. Copyright The Physiological Society (1963) 
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Additional figures for the publication: 
 
A photograph of Professor Gus Born during the interview in 2013  
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A postcard to Gayle Halford from Gus after the 2013 UK Platelet Meeting held 
in Birmingham, UK. 
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 Another postcard from Gus to Gayle Halford commenting on the science at the 
2013 UK Platelet Meeting held in Birmingham, UK. 
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